BGF World Healthscience Fund Hedged A2 AUD
LU1023059063
BGF World Healthscience Fund Hedged A2 AUD/ LU1023059063 /
NAV18/10/2024 |
Chg.-0.0300 |
Type of yield |
Investment Focus |
Investment company |
23.4400AUD |
-0.13% |
reinvestment |
Equity
Worldwide
|
BlackRock (LU) ▶ |
Investment strategy
The Fund aims to maximise the return on your investment through a combination of capital growth and income on the Fund"s assets and invest in a manner consistent with the principles of environmental, social and governance (ESG) investing. The Fund invests globally at least 70% of its total assets in the equity securities (e.g. shares) of companies the main business of which is in healthcare, pharmaceuticals, medical technology and supplies and the development of biotechnology.
The investment adviser (IA) may use financial derivative instruments (FDIs) (i.e. investments the prices of which are based on one or more underlying assets) for investment purposes in order to achieve the investment objective of the Fund, and/or to reduce risk within the Fund"s portfolio, reduce investment costs and generate additional income. The Fund may, via FDIs, generate varying amounts of market leverage (i.e. where the Fund gains market exposure in excess of the value of its assets). The Fund is actively managed, and the IA has discretion to select the Fund's investments. In doing, the IA will refer to the MSCI World Health Care Index (the "Index") when constructing the Fund"s portfolio, and also for performance comparison and risk management purposes, as further described in the prospectus. The IA is not bound by the components or weighting of the Index. and may also use its discretion to invest in securities not included in the Index. However, the sector requirements of the investment objective and policy may limit the extent to which the portfolio holdings will deviate from the Index.
Investment goal
The Fund aims to maximise the return on your investment through a combination of capital growth and income on the Fund"s assets and invest in a manner consistent with the principles of environmental, social and governance (ESG) investing. The Fund invests globally at least 70% of its total assets in the equity securities (e.g. shares) of companies the main business of which is in healthcare, pharmaceuticals, medical technology and supplies and the development of biotechnology.
Master data
Type of yield: |
reinvestment |
Funds Category: |
Equity |
Region: |
Worldwide |
Branch: |
Sector Health / Pharma |
Benchmark: |
MSCI World Health Care Index |
Business year start: |
01/09 |
Last Distribution: |
- |
Depository bank: |
The Bank of New York Mellon SA/NV, Zweigniederlassung Luxemburg |
Fund domicile: |
Luxembourg |
Distribution permission: |
Austria, Germany, Switzerland, United Kingdom, Luxembourg, Czech Republic |
Fund manager: |
Erin Xie, Xiang Liu |
Fund volume: |
14.8 bill.
USD
|
Launch date: |
26/02/2014 |
Investment focus: |
- |
Conditions
Issue surcharge: |
5.00% |
Max. Administration Fee: |
1.50% |
Minimum investment: |
5,000.00 AUD |
Deposit fees: |
0.45% |
Redemption charge: |
0.00% |
Key Investor Information: |
Download (Print version) |
Investment company
Funds company: |
BlackRock (LU) |
Address: |
35a Avenue JF Kennedy, 1855, Luxemburg |
Country: |
Luxembourg |
Internet: |
www.blackrock.com
|
Assets
Stocks |
|
96.93% |
Mutual Funds |
|
2.74% |
Cash |
|
0.33% |
Countries
United States of America |
|
69.95% |
Denmark |
|
6.24% |
Switzerland |
|
6.03% |
United Kingdom |
|
4.48% |
France |
|
3.95% |
Ireland |
|
1.45% |
Germany |
|
1.19% |
Netherlands |
|
1.19% |
Australia |
|
1.03% |
Japan |
|
0.90% |
Belgium |
|
0.45% |
Cash |
|
0.33% |
Others |
|
2.81% |
Branches
Pharma/Biotechnology |
|
50.78% |
Healthcare services |
|
21.59% |
Healthcare appliances |
|
19.84% |
Parma, wholesale |
|
4.68% |
Cash |
|
0.33% |
Others |
|
2.78% |